BioGrad, a prominent laboratory technology firm, is expanding into Yorkshire with a significant £3m investment, marking a pivotal step in its national growth strategy.
- The new research and teaching facility in York aims to position BioGrad at the forefront of scientific and healthcare advancements in the UK.
- By 2025, BioGrad anticipates leading a nationwide clinical trial, leveraging the strengths of York’s world-class NHS Trust and universities.
- Since 2022, BioGrad has successfully established labs across major UK cities, contributing to its rapid expansion and job creation.
- Driven by partnerships with regional authorities, the expansion underscores BioGrad’s commitment to innovation and regional development.
Laboratory technology firm BioGrad has embarked on an ambitious expansion into Yorkshire, bolstering its national presence with a £3m investment. This strategic move involves establishing a new research and teaching site in York, an initiative designed to enhance BioGrad’s role in the science, healthcare, and regenerative medicine sectors. BioGrad’s expansion is seen as a significant milestone, reflecting its ongoing commitment to pioneering clinical research and education across the UK.
The York facility is intended to be a hub for cutting-edge research, positioning BioGrad at the forefront of scientific innovation. With plans to lead a comprehensive nationwide clinical trial in 2025, the firm capitalizes on the region’s highly regarded NHS Trust and academic institutions. Dr Natalie Kenny, CEO of BioGrad, highlights the strategic importance of York: “The help and support BioGrad has received from local authorities make York our preferred choice for expanding operations.”
Since 2022, BioGrad has launched labs in Birmingham, Newcastle, and London, each adding substantial value to its operational capabilities. The company’s headquarters, located at Wavertree Technology Park in Liverpool, anchors its UK operations. These expansions contribute significantly to BioGrad’s workforce, with the firm now employing approximately 150 professionals. Such growth milestones underline BioGrad’s robust presence in the UK’s scientific landscape.
BioGrad’s recent accomplishments include being the first North West company to secure investment from the £660m Northern Powerhouse Investment Fund II, a testament to its rapidly growing influence and strategic importance. Partnerships with regional authorities in York and North Yorkshire have been crucial in facilitating this expansion. The cooperative efforts of local government officials, such as Sector Development Relationship Manager Sophie Hartley and Inward Investment Manager Christine Hogan, have been pivotal in bringing BioGrad’s research capabilities to York.
David Skaith, Mayor of York and North Yorkshire, warmly welcomed BioGrad’s investment in the region, noting its potential to create high-quality skilled jobs in an expanding sector. The demographic strengths of York, combined with its rich array of research centres and universities, are expected to propel the city to a prominent position within the global healthcare industry, aligning with BioGrad’s strategic ambitions.
BioGrad’s investment in Yorkshire represents a strategic expansion aimed at reinforcing its national prominence and driving scientific innovation.
